ArticleEClinicalMedicine2025
Effect of neoadjuvant therapy on survival outcomes in patients with melanoma: a systematic review and meta-analysis.
Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of priori dietary patterns with metabolic syndrome and its components: a systematic review and meta-analysis.Frontiers in nutrition · 2026Pooled it
- A Coordinated Approach to Perioperative Rehabilitation to Enhance Outcomes in Melanoma: Protocol for the CARE-Melanoma Pilot Randomized Controlled Trial.JMIR research protocols · 2026Article
- Novel insights into extracellular vesicles: An update on biomolecules, immunomodulation and clinical strategies in skin melanoma.Clinical and translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Melanoma is the most aggressive type of skin cancer, and its advanced cases often have a poor prognosis due to early metastasis. In recent years, neoadjuvant therapy (NT) has demonstrated potential benefits in treating solid tumours. However, its efficacy and safety in treating melanoma remain inconclusive. This study aimed to evaluate the complete response (CR), survival outcomes, and safety of NT in patients with melanoma. Methods: In this systematic review and meta-analysis, Cochrane, Web of Science, Embase, and PubMed were searched up to 24 February 2025, and the Clinical Trial Registry was also search to identify additional eligible studies. Studies were included if they involved patients with melanoma receiving NT, with or without a comparator group. Both randomised controlled trials and non-randomised studies were eligible. In comparative studies, only those with adjuvant therapy or surgery alone as the comparator were included. Regardless of study design, all analyses were centred on the NT groups. Two reviewers separately screened the literature, extracted data, and evaluated the risk of bias. The quality of the included studies was appraised using National Institutes of Health study quality assessment tool (NIH-QAT). Data analysis was conducted through Stata 15.0 and R 4.4.1. After heterogeneity analysis of Cochrane's Q test and Findings: A total of 43 studies involving 2821 patients with melanoma who received NT were included. Based on the NIH-QAT, the overall quality of the included studies was considered good. Meta-analysis showed that the pooled pCR was 33% (95% CI: 27%-39%, Interpretation: Current evidence suggests that NT in patients with melanoma is associated with a favourable CR and promising survival benefits without increasing the risk of severe AEs. Compared to AT, NT demonstrates potential advantages in reducing the risks of disease progression and death. However, the results of this study s should be considered exploratory since the majority of included studies are single-arm or observational studies. Further high-quality randomised trials are needed to confirm the long-term efficacy and safety of NT. Funding: None.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.